Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial

被引：0

作者：

O Nehls

B Klump

H T Arkenau

H G Hass

A Greschniok

M Gregor

R Porschen

机构：

[1] University Hospital,Department of Internal Medicine I

[2] University Hospital,Department of Pathology

[3] Clinic of Internal Medicine,undefined

[4] Central Hospital Bremen Ost,undefined

来源：

British Journal of Cancer | 2002年 / 87卷

关键词：

biliary carcinoma; chemotherapy; 5-fluorouracil; oxaliplatin;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas. The disease control rate (responses and stable disease) was 56% (95% confidence interval, 29–84%) and the median overall survival time was 9.5 months (range 0.9–26.8+). Therefore, this regimen might be active in biliary adenocarcinomas with further evaluation necessary.

引用

页码：702 / 704

页数：2

共 50 条

[1] Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial
Nehls, O
Klump, B
Arkenau, HT
Hass, HG
Greschniok, A
Gregor, M
Porschen, R
BRITISH JOURNAL OF CANCER, 2002, 87 (07) : 702 - 704
[2] A prospective multicenter phase II trial of capecitabine plus oxaliplatin (CAPOX) in advanced biliary system adenocarcinomas
Nehls, O.
Oettle, H.
Hartmann, J. T.
Hofheinz, R.
Hass, H. G.
Hochhaus, A.
Makowski, M.
Arnold, D.
Gregor, M.
Klump, B.
EJC SUPPLEMENTS, 2005, 3 (02): : 212 - 212
[3] Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus
Mauer, AM
Kraut, EH
Krauss, SA
Ansari, RH
Kasza, K
Szeto, L
Vokes, EE
ANNALS OF ONCOLOGY, 2005, 16 (08) : 1320 - 1325
[4] Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for rccurrent/metastatic biliary tract carcinoma
Lim, Jae Yun
Jeung, Hei-Cheul
Mun, Hee Sun
Lee, Dong Ki
Paik, Yong Han
Lee, Se Joon
Yoon, Dong Sup
Cho, Jae Yong
ANTI-CANCER DRUGS, 2008, 19 (06) : 631 - 635
[5] A prospective multicenter phase II trial of capecitabine plus oxaliplatin (CapOx) in advanced biliary system adenocarcinomas:: The final results.
Nehls, O.
Oettle, H.
Hartmann, J.
Hofheinz, R.
Hass, H.
Hochhaus, A.
Stieler, J.
Koppenhöfer, U.
Gregor, M.
Klump, B.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 211S - 211S
[6] Oxaliplatin, irinotecan, and 5-fluorouracil/leucovorin in advanced gastric adenocarcinoma: A phase II trial
Comella, P.
Lorusso, V.
Maiorino, L.
Casaretti, R.
Cannone, M.
Massidda, B.
Farris, A.
Leo, S.
Roselli, M.
Sandomenico, C.
Mancarella, S.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[7] Phase II trial of oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for advanced biliary tract adenocarcinoma.
Porschen, R
Nehls, O
Bermann, A
Burkart, C
Gregor, M
GASTROENTEROLOGY, 1999, 116 (04) : A487 - A487
[8] A multicenter phase II study of capecitabine plus oxaliplatin (CapOx) in advanced biliary system adenocarcinomas.
Nehls, O
Oettle, H
Hartmann, JT
Hofheinz, R
Hochhaus, A
Makowski, M
Arnold, D
Burkart, C
Gregor, M
Klump, B
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 336S - 336S
[9] Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer
McWilliams, Robert R.
Goetz, Matthew P.
Morlan, Bruce W.
Salim, Muhammad
Rowland, Kendrith M.
Krook, James E.
Ames, Matthew M.
Erlichman, Charles
CLINICAL COLORECTAL CANCER, 2007, 6 (07) : 516 - 521
[10] Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors - A phase II trial
Ollivier, S
Fonck, M
Becouarn, Y
Brunet, R
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (03): : 237 - 240

← 1 2 3 4 5 →